JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guo", 
        "givenName": "Lixin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Ningbo First Hospital, Zhejiang, China", 
          "id": "http://www.grid.ac/institutes/grid.416271.7", 
          "name": [
            "Department of Endocrinology, Ningbo First Hospital, Zhejiang, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Changshu Second People\u2019s Hospital, Jiangsu, China", 
          "id": "http://www.grid.ac/institutes/grid.440299.2", 
          "name": [
            "Department of Endocrinology, Changshu Second People\u2019s Hospital, Jiangsu, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Qiurong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Na", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.268099.c", 
          "name": [
            "Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Jun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Zhiquan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ding", 
        "givenName": "Yuchen", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-020-00804-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1126593766", 
          "https://doi.org/10.1007/s13300-020-00804-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0646-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117299789", 
          "https://doi.org/10.1007/s13300-019-0646-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-020-00839-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1128395219", 
          "https://doi.org/10.1007/s13300-020-00839-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-021-01079-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138437570", 
          "https://doi.org/10.1007/s13300-021-01079-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-18", 
    "datePublishedReg": "2022-05-18", 
    "description": "BackgroundTRUST-CHN is a prospective, post-marketing safety study in patients with type 2\u00a0diabetes mellitus (T2DM) in China to evaluate the safety and effectiveness of dulaglutide in real-world clinical practice. We report here the study design and baseline characteristics of enrolled patients.MethodsThe study design was described, and baseline data were analyzed, including demographic characteristics, T2DM duration, comorbidities, dulaglutide treatment patterns, and concomitant medications.ResultsFor the present analysis of this ongoing study, data were collected from January 2020 to November 2021. A total of 3313 patients were enrolled, of whom 3294 patients were included in the safety analysis. In total, 1047 patients had a prior history of dulaglutide use before being enrolled in the study. The mean (standard deviation [SD]) age of study subjects was 50.1\u00a0(13.2)\u00a0years, 85.1% were aged\u2009<\u200965\u00a0years; 67.9% were male, and 35.9% had an education of university level or higher. Mean (SD) duration of T2DM was 6.4 (6.7) years. Baseline mean (SD) glycated hemoglobin was 8.8% (2.2%), and mean (SD) body mass index was 28.1 (4.1) kg/m2. A total of 2867\u00a0(87%) patients had at least one comorbidity, the most frequently reported of which were overweight/obesity (87.1%), hyperlipidemia (50.5%), hypertension (47.9%), diabetic neuropathy (18.9%), and coronary artery disease (15.7%). Almost all (99.7%) patients were treated with 1.5\u00a0mg dulaglutide; at baseline, 24.8% were treated with this medication as monotherapy and 75.2% in combination therapy with other medications, including metformin (42.3%), sodium glucose co-transporter2 inhibitor (26.7%), insulin (18.3%), \u03b1-glucosidase inhibitor (13.1%), sulfonylurea (5.3%), dipeptidyl peptidase 4 inhibitor (4.4%), glucagon-like peptide 1 receptor agonist (2.7%), and thiazolidinedione (2.4%).ConclusionThe present analysis revealed real-world baseline characteristics of patients with T2DM in China who use dulaglutide enrolled in TRUST-CHN. These data will enable further exploration of the characteristics of patients with T2DM in China and provide an insight on the current use of dulaglutide in clinical practice.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01268-2", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "post-marketing safety studies", 
      "baseline characteristics", 
      "study design", 
      "glucagon-like peptide-1 receptor agonists", 
      "clinical practice", 
      "sodium glucose co-transporter2 (SGLT2) inhibitors", 
      "peptide-1 receptor agonists", 
      "dipeptidyl peptidase-4 inhibitors", 
      "real-world clinical practice", 
      "safety studies", 
      "characteristics of patients", 
      "overweight/obesity", 
      "coronary artery disease", 
      "peptidase-4 inhibitors", 
      "body mass index", 
      "MethodsThe study design", 
      "T2DM duration", 
      "concomitant medications", 
      "diabetic neuropathy", 
      "diabetes mellitus", 
      "treatment patterns", 
      "artery disease", 
      "mass index", 
      "mean age", 
      "combination therapy", 
      "mean duration", 
      "receptor agonist", 
      "dulaglutide", 
      "prior history", 
      "patients", 
      "study subjects", 
      "T2DM", 
      "type 2", 
      "baseline mean", 
      "medications", 
      "\u03b1-glucosidase inhibitors", 
      "demographic characteristics", 
      "baseline data", 
      "comorbidities", 
      "ongoing studies", 
      "inhibitors", 
      "current use", 
      "total", 
      "duration", 
      "further exploration", 
      "years", 
      "hypertension", 
      "monotherapy", 
      "mellitus", 
      "hyperlipidemia", 
      "neuropathy", 
      "obesity", 
      "metformin", 
      "thiazolidinediones", 
      "therapy", 
      "agonists", 
      "sulfonylureas", 
      "insulin", 
      "disease", 
      "study", 
      "present analysis", 
      "baseline", 
      "hemoglobin", 
      "age", 
      "subjects", 
      "safety", 
      "safety analysis", 
      "data", 
      "use", 
      "practice", 
      "index", 
      "levels", 
      "history", 
      "analysis", 
      "characteristics", 
      "m2", 
      "patterns", 
      "effectiveness", 
      "education", 
      "China", 
      "means", 
      "design", 
      "insights", 
      "exploration", 
      "university level"
    ], 
    "name": "Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN)", 
    "pagination": "1231-1244", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147961996"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01268-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35583797"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01268-2", 
      "https://app.dimensions.ai/details/publication/pub.1147961996"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_953.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01268-2"
  }
]

Download the RDF metadata as:  json-ld nt turtle xml License info

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      114 URIs      102 LITERALS      7 BLANK NODES